| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/14/2011 | US20110086072 Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact With the Corresponding Antigen |
| 04/14/2011 | US20110086071 Pharmaceutical Compositions Comprising Terbinafine |
| 04/14/2011 | US20110086070 Orally disintegrating compositions of rhein or diacerein |
| 04/14/2011 | US20110086069 Pharmaceutical formulations of nitrite and uses thereof |
| 04/14/2011 | US20110086068 Compositions and Methods for Tissue Engineering, Tissue Regeneration and Wound Healing |
| 04/14/2011 | US20110086021 Sclerostin and the inhibition of WNT signaling and bone formation |
| 04/14/2011 | US20110085989 Novel antimicrobial peptides |
| 04/14/2011 | US20110085987 Folic acid-mediated magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications |
| 04/14/2011 | US20110083991 Hyaluronic acid derivative and drug containing the same |
| 04/14/2011 | US20110083668 Sealed capsule including an integrated puncturing mechanism |
| 04/14/2011 | DE112008003744T5 Fettemulsion, umfassend Ganoderma-Sporenöl, Verfahren zur Qualitätskontrolle und Verwendung davon Fat emulsion comprising Ganoderma spore oil, quality control procedures and use thereof |
| 04/14/2011 | DE102010016485A1 Verfahren zum Herstellen eines Stoffs mit einstellbaren biologisch aktiven Gradienteneigenschaften und Verwendung des Verfahrens A method for producing a biologically active substance with adjustable Gradienteneigenschaften and use of the method |
| 04/14/2011 | CA2785315A1 Formulation of drugs and vaccines in the form of percutaneous injectable needles |
| 04/14/2011 | CA2776921A1 A composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof |
| 04/14/2011 | CA2776748A1 Use of pedf in an encapsulated cell-based delivery system |
| 04/14/2011 | CA2775603A1 Carrageenan-containing aqueous antimicrobial compositions |
| 04/14/2011 | CA2775089A1 Low ether composition and delivery apparatus |
| 04/14/2011 | CA2774963A1 Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease |
| 04/14/2011 | CA2774720A1 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
| 04/13/2011 | EP2308916A1 Polymer/metal complex composite having mri contrast ability and mri contrasting and/or antitumor composition using the same |
| 04/13/2011 | EP2308878A2 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and use as medicaments |
| 04/13/2011 | EP2308864A1 Pharmaceutical formulation of duloxetine hydrochloride |
| 04/13/2011 | EP2308563A1 Risedronic acid for treatment and prevention of bone resorption diseases |
| 04/13/2011 | EP2308522A2 Microfabricated devices for the delivery of molecules into a carrier fluid |
| 04/13/2011 | EP2308512A1 Water-containing composition |
| 04/13/2011 | EP2308511A1 Tablet quickly disintegrating in the oral cavity and method for producing the same |
| 04/13/2011 | EP2308502A1 Method to induce neovascular formation and tissue regeneration |
| 04/13/2011 | EP2308501A1 Platelet-derived growth factor compositions and methods of use thereof |
| 04/13/2011 | EP2308500A1 Platelet-derived growth factor compositions and methods of use thereof |
| 04/13/2011 | EP2308497A1 Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers |
| 04/13/2011 | EP2308496A2 Formulation containing phosphate derivatives of electron transfer agents |
| 04/13/2011 | EP2308494A1 Tamper resistant dosage forms |
| 04/13/2011 | EP2308493A1 Ameliorating or therapeutic agent for dyslipidemia |
| 04/13/2011 | EP2308487A1 An entacapone-containing oral dosage form |
| 04/13/2011 | EP2308483A1 Process for production of spherical microparticles comprising tamsulosin hydrochloride |
| 04/13/2011 | EP2308480A2 High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications |
| 04/13/2011 | EP2308479A2 Compounds and compositions for delivering active agents |
| 04/13/2011 | EP2308478A1 Delivery system for sustained release of a calcium-channel blocking agent |
| 04/13/2011 | EP2308477A1 Delayed release rasagiline formulation |
| 04/13/2011 | EP2308476A1 Colonic purgative composition with soluble binding agent |
| 04/13/2011 | EP2308475A1 Matrix for sustained, invariant and independent release of active compounds |
| 04/13/2011 | EP2308474A1 Matrix for sustained, invariant and independent release of active compounds |
| 04/13/2011 | EP2308473A1 Pharmaceutical composition containing surface-coated microparticles |
| 04/13/2011 | EP2308472A1 Pharmaceutical compositions comprising rivaroxaban |
| 04/13/2011 | EP2308471A1 Process for modifying drug crystal formation |
| 04/13/2011 | EP2308470A1 Sustained-release liposomal anesthetic compositions |
| 04/13/2011 | EP2308469A1 Formulations for alteration of biophysical properties of mucosal lining |
| 04/13/2011 | EP2308468A1 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
| 04/13/2011 | EP2308467A2 Liquid pharmaceutical formulations of docetaxel |
| 04/13/2011 | EP2308466A1 Aqueous pharmaceutical compositions containing borate-polyol complexes |
| 04/13/2011 | EP2308465A2 Transmucosal drug delivery device and method including chemical permeation enhancers |
| 04/13/2011 | EP2308464A1 Orally disintegrating compositions of pramipexole |
| 04/13/2011 | EP2308463A1 Aqueous acetaminophen compositions and method of preparation |
| 04/13/2011 | EP2308456A1 Water-in-oil emulsions comprising vinyl polymers carrying ethylene oxide groups in side chains, compositions, and methods |
| 04/13/2011 | EP2308431A1 Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use |
| 04/13/2011 | EP2308428A1 Device and method for reversible office sterilization |
| 04/13/2011 | EP2307444A1 Analysis of lactobacillus acidophilus la-5 signal interference molecules |
| 04/13/2011 | EP2307129A2 Microcapsules comprising active ingredients and a metal oxide shell, a method for their preparation and uses thereof |
| 04/13/2011 | EP2307090A2 Method and system for recording and promoting peripheral nerve regeneration |
| 04/13/2011 | EP2307057A1 Manufacturing method of collagen gel composition for bone regeneration |
| 04/13/2011 | EP2307054A2 Edible holographic silk products |
| 04/13/2011 | EP2307021A1 Formulations |
| 04/13/2011 | EP2306999A2 Compositions for treating rosacea |
| 04/13/2011 | EP2306998A1 Pharmaceutical formulation |
| 04/13/2011 | EP2306993A1 Protamine/rna nanoparticles for immunostimulation |
| 04/13/2011 | EP2306992A2 Delivery particle |
| 04/13/2011 | EP2306991A2 Injectable delivery of microparticles and compositions therefore |
| 04/13/2011 | EP2306990A1 Pharmaceutical composition comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1 h-pyrrole-3-carboxamide |
| 04/13/2011 | EP2306989A2 Fenofibrate formulation with enhanced oral bioavailability |
| 04/13/2011 | EP2306988A1 Pharmaceutical formulation for treating the upper digestive tract |
| 04/13/2011 | EP2306987A1 Method for coating tablets |
| 04/13/2011 | EP2306986A1 Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| 04/13/2011 | EP2306985A2 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| 04/13/2011 | EP2306984A1 Pharmaceutical dosage form for the site-specific delivery of more than one active pharmaceutical ingredient |
| 04/13/2011 | EP2306983A1 A gastroretentive pharmaceutical dosage form |
| 04/13/2011 | EP2306982A1 Pharmaceutical compositions of rosuvastatin calcium |
| 04/13/2011 | EP2306981A1 A transmucosal delivery system |
| 04/13/2011 | EP2306980A2 Powders for reconstitution |
| 04/13/2011 | EP2306979A1 Liposomes capable of effectively binding the beta amyloid peptide |
| 04/13/2011 | EP2306978A2 Compositions for the in vivo delivery of rnai agents |
| 04/13/2011 | EP2306977A1 Method and composition for treating ocular hypertension and glaucoma |
| 04/13/2011 | EP2306976A2 Injectable taxane pharmaceutical composition |
| 04/13/2011 | EP2306975A2 Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
| 04/13/2011 | EP2306974A1 A topical composition comprising the isolated non-polar lipid fraction of lan0lin4 |
| 04/13/2011 | EP2306973A1 Vaginal suppository comprising lactic acid |
| 04/13/2011 | EP2306972A1 Acetic acid and a buffer |
| 04/13/2011 | EP2306971A1 Unit dosage of apadenoson |
| 04/13/2011 | EP2306848A1 Sugar micro/nanofoams |
| 04/13/2011 | EP2306839A1 Gacyclidine formulations |
| 04/13/2011 | EP2306829A1 Particles containing an opioid receptor antagonist and methods of use |
| 04/13/2011 | EP2306825A1 Inhibitors of akt activity |
| 04/13/2011 | EP2306824A1 Iontophoretic delivery of curcumin and curcumin analogs for the treatment of alzheimer's disease |
| 04/13/2011 | EP2306823A1 Formulations of 5-fluorocytosine and uses thereof |
| 04/13/2011 | EP1926472B1 Stabilized and preserved ketotifen ophthalmic compositions |
| 04/13/2011 | EP1796644B1 Drug delivery from embolic agents |
| 04/13/2011 | EP1781275B1 Sustained release pharmaceutical composition of tolterodine |
| 04/13/2011 | EP1720531B1 New compositions containing quinoline compounds |
| 04/13/2011 | EP1699847B1 Method for the preparation of medicinal compositions |
| 04/13/2011 | EP1697033B1 Process for cryogranulation and storage of allergens |
| 04/13/2011 | EP1636295B1 Drug delivery device comprising an active compound and method for releasing an active compound from a drug delivery device |